Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides.
OBJECTIVE
A microparticle carrier based on alginate and poly-L-lysine was developed and evaluated for the delivery of antisense oligonucleotides at the intestinal site. Formulations of oligonucleotide-loaded microparticles having differences in the carrier molecular weight and composition were characterized in vitro and in vivo.


METHODS
Polymeric microparticles were prepared by ionotropic gelation and crosslinking of alginate with calcium ions and poly-L-lysine. The loading of the antisense oligonucleotide into the microparticles was achieved by absorption in aqueous medium. The association capacity, loading and particle size of the microparticles were characterized. The in vivo performances of various formulations after intrajejunal administration were studied in rat and in dog models.


RESULTS
Microparticles had a sponge-like structure and an oligonucleotide loading of 27-35%. The composition of the medium affected the particle size and the in vitro release profiles. The oligonucleotide bioavailability after intrajejunal administration to rats in the presence of permeation enhancers was good for most of the tested systems. The application of microparticles in powder form compared to an equivalent suspension improved the intrajejunal bioavailability of the oligonucleotide (25% and 10% respectively) in rats. On the contrary, the intrajejunal administration to dogs resulted in poor oligonucleotide bioavailability (0.42%).


CONCLUSIONS
The formulation of antisense oligonucleotides within alginate and poly-L-lysine microparticles is a promising strategy for the oral application.
González Ferreiro
María
M
College of Pharmacy, Freie Universität Berlin, Germany.
Tillman
Lloyd G
LG
Hardee
Gregory
G
Bodmeier
Roland
R
D000464:Alginates / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D000818:Animals; D004285:Dogs; D016503:Drug Delivery Systems / Q000379:methods*; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008863:Microspheres; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D011107:Polylysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000464:Alginates; D016376:Oligonucleotides, Antisense; C051546:alginate-polylysine-alginate; D011107:Polylysine